Keith Morrison

882 total citations
16 papers, 696 citations indexed

About

Keith Morrison is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Keith Morrison has authored 16 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 5 papers in Molecular Biology. Recurrent topics in Keith Morrison's work include Pulmonary Hypertension Research and Treatments (6 papers), Nitric Oxide and Endothelin Effects (5 papers) and Sphingolipid Metabolism and Signaling (4 papers). Keith Morrison is often cited by papers focused on Pulmonary Hypertension Research and Treatments (6 papers), Nitric Oxide and Endothelin Effects (5 papers) and Sphingolipid Metabolism and Signaling (4 papers). Keith Morrison collaborates with scholars based in Switzerland, Australia and Fiji. Keith Morrison's co-authors include Martine Clozel, Patrick Hess, John Gatfield, Walter Fischli, Christoph A. Binkert, Thomas Weller, Martin H. Bolli, Changbin Qiu, Stephan Buchmann and Christoph Boss and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Journal of Medicinal Chemistry.

In The Last Decade

Keith Morrison

16 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keith Morrison Switzerland 9 355 344 145 139 121 16 696
Markus Rey Switzerland 16 314 0.9× 367 1.1× 153 1.1× 222 1.6× 213 1.8× 29 934
Patricia N. Sidharta Switzerland 20 610 1.7× 628 1.8× 407 2.8× 131 0.9× 125 1.0× 57 1.1k
Karen B. Jourdan United Kingdom 9 383 1.1× 148 0.4× 110 0.8× 56 0.4× 152 1.3× 10 619
Sigrun Unger Germany 13 386 1.1× 538 1.6× 229 1.6× 50 0.4× 157 1.3× 37 891
Dany Salvail Canada 17 171 0.5× 112 0.3× 164 1.1× 203 1.5× 147 1.2× 26 672
Peter G. Linde United States 10 316 0.9× 240 0.7× 56 0.4× 71 0.5× 262 2.2× 25 828
Shintaro Nishio Japan 13 129 0.4× 144 0.4× 112 0.8× 67 0.5× 80 0.7× 29 437
Masaki Sano Japan 18 361 1.0× 118 0.3× 79 0.5× 330 2.4× 231 1.9× 64 974
Keiichi Kuwano Japan 6 224 0.6× 160 0.5× 61 0.4× 30 0.2× 67 0.6× 9 358
Jacek Owczarek Poland 11 79 0.2× 112 0.3× 58 0.4× 165 1.2× 137 1.1× 39 572

Countries citing papers authored by Keith Morrison

Since Specialization
Citations

This map shows the geographic impact of Keith Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Morrison more than expected).

Fields of papers citing papers by Keith Morrison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Morrison. The network helps show where Keith Morrison may publish in the future.

Co-authorship network of co-authors of Keith Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Morrison. A scholar is included among the top collaborators of Keith Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Morrison. Keith Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Lescop, Cyrille, Christine Brotschi, Christoph P. Sager, et al.. (2024). Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold. Journal of Medicinal Chemistry. 67(4). 2379–2396. 2 indexed citations
2.
Lescop, Cyrille, Magdalena Birker, Christine Brotschi, et al.. (2024). Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases. Journal of Medicinal Chemistry. 67(4). 2397–2424. 4 indexed citations
3.
Morrison, Keith, et al.. (2023). Postcolonial lessons and migration from climate change: ongoing injustice and hope. SHILAP Revista de lepidopterología. 2(1). 3 indexed citations
4.
Morrison, Keith, et al.. (2018). Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery. Journal of Pharmacology and Experimental Therapeutics. 365(3). 727–733. 6 indexed citations
5.
Gatfield, John, Katalin Menyhart, Carmela Gnerre, et al.. (2017). Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential. Journal of Pharmacology and Experimental Therapeutics. 362(1). 186–199. 27 indexed citations
6.
Piali, Luca, Magdalena Birker, Cyrille Lescop, et al.. (2017). Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties. Pharmacology Research & Perspectives. 5(6). 26 indexed citations
7.
Rey, Markus, Patrick Hess, Keith Morrison, et al.. (2017). The reversible P2Y12antagonist ACT‐246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat. Pharmacology Research & Perspectives. 5(5). 24 indexed citations
8.
Morrison, Keith, et al.. (2015). REPEATED ORAL ADMINISTRATION OF THE SELECTIVE PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG DOES NOT CAUSE TACHYPHYLAXIS IN SPONTANEOUSLY HYPERTENSIVE RATS. Journal of the American College of Cardiology. 65(10). A1558–A1558. 7 indexed citations
9.
Gatfield, John, Katalin Menyhart, Keith Morrison, & Oliver Nayler. (2015). THE NON-PROSTANOID PROSTACYCLIN RECEPTOR AGONIST ACT-333679, THE ACTIVE METABOLITE OF SELEXIPAG, IS CHARACTERIZED BY LOW BETA-ARRESTIN RECRUITMENT AND RECEPTOR INTERNALIZATION ACTIVITY. Journal of the American College of Cardiology. 65(10). A1542–A1542. 6 indexed citations
10.
Asaki, Tetsuo, Keiichi Kuwano, Keith Morrison, et al.. (2015). Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. Journal of Medicinal Chemistry. 58(18). 7128–7137. 69 indexed citations
11.
Morrison, Keith, et al.. (2012). Differential Effects of Selexipag and Prostacyclin Analogs in Rat Pulmonary Artery. Journal of Pharmacology and Experimental Therapeutics. 343(3). 547–555. 42 indexed citations
12.
Morrison, Keith, et al.. (2010). Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric Function. Journal of Pharmacology and Experimental Therapeutics. 335(1). 249–255. 52 indexed citations
13.
Iglarz, Marc, Christoph A. Binkert, Keith Morrison, et al.. (2008). Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics. 327(3). 736–745. 260 indexed citations
14.
Clozel, Martine, Christoph A. Binkert, Magdalena Birker, et al.. (2004). Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System. Journal of Pharmacology and Experimental Therapeutics. 311(1). 204–212. 108 indexed citations
15.
Bolli, Martin H., Corinna Grisostomi, Christoph Boss, et al.. (2004). Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists. Journal of Medicinal Chemistry. 47(11). 2776–2795. 59 indexed citations
16.
Morrison, Keith, et al.. (1990). Subsensitivity to agonists in blood vessels from spontaneously hypertensive rats. European Journal of Pharmacology. 183(3). 834–834. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Markus Rey Breakdown of academic impact, for papers by Patricia N. Sidharta Breakdown of academic impact, for papers by Karen B. Jourdan Breakdown of academic impact, for papers by Sigrun Unger Breakdown of academic impact, for papers by Dany Salvail Breakdown of academic impact, for papers by Peter G. Linde Breakdown of academic impact, for papers by Shintaro Nishio Breakdown of academic impact, for papers by Masaki Sano Breakdown of academic impact, for papers by Keiichi Kuwano Breakdown of academic impact, for papers by Jacek Owczarek
Rankless by CCL
2026